Covishield gives 93% protection against Covid, finds AFMC study

Addressing a press conference, NITI Aayog Member (Health) Dr V K Paul presented findings of the study which was conducted on 15 lakh doctors and frontline workers.

Covishield, Covid-19 vaccine
Press Trust of India New Delhi
1 min read Last Updated : Jul 27 2021 | 7:56 PM IST

Covishield gives 93 per cent protection against COVID-19 and a 98 per cent mortality reduction, the government said on Tuesday referring to a study by the Armed Forces Medical College (AFMC) during the second COVID-19 wave that was driven by the Delta variant.

Addressing a press conference, NITI Aayog Member (Health) Dr V K Paul presented findings of the study which was conducted on 15 lakh doctors and frontline workers.

"Protection to the extent of 93 per cent was seen (in people who were administered the Covishield vaccine) and this was during the second wave which was driven by the Delta variant... also 98 per cent mortality reduction was seen," he said.

Reiterating the usefulness of vaccines in battling COVID-19, Paul said inoculation reduces infection but it is not a total guarantee.

"No vaccine guarantees that infection will not happen but serious disease gets prevented and nearly eliminated. I urge you to please be vigilant, be careful, have faith in our vaccines and continue to be careful in the weeks and months ahead," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 27 2021 | 7:56 PM IST

Next Story